Xifaxan is an effective antibacterial product which is used for the treatment of the enteric infections. It contains the active ingredient rifaximin which has been approved by FDA.
Irritable bowel syndrome has a lot of symptoms: stomachache, flatulency, diarrhea, and others. The basic cause of this syndrome can be morbific bacteria which are actively developed in the intestine.
Xifaxan antibiotic has a broad action but it is poorly absorbed in the systemic blood flow from the gastro-intestinal tract. Due to this, Rifaximin is concentrated in the intestinal lumen and actively inhibits a development of microorganisms.
As to microorganisms, Xifaxan provides a bactericidal action and it helps to neutralize the activity of the morbific bacteria in the gastro-intestinal tract.
The medicine is not used for the treatment of infections of other site because the concentration of Xifaxan is insignificant in the systemic blood flow. Xifaxan is effective as to infections caused by colibacilli, but the medicine hardly inhibits the activity of bacteria causing dysentery, salmonella, and others. Therefore, before the treatment, it is necessary to have an examination and detect the type of the originator of the infection.
Xifaxan lowers a formation of ammonia and other toxic compounds which take part in pathogeny of hepatic encephalopathy in case of the severe liver disease.
Directions for the use
Xifaxan is indicated for the gastro-intestinal infections which are caused by sensitive originators:
Xifaxan is used for the prevention of the infectious complications during the surgeries in large intestine.
Usage and dosage
Xifaxan can be used by children over 12 years and adults. The pills are used orally and with a full glass of water. As the antibiotic is not absorbed from the GIT, period of use and consumed food do not influence on therapeutic characteristics of the active ingredients.
In the treatment of the intestinal infections, patients are prescribed Xifaxan 400 mg 3 times per day (every 8 hours). The treatment lasts for 7 days, and then a medical examination and a result control are needed.
If the symptoms of the enteric infection are reduced but the morbific bacteria are still there, a 7-day-course of the treatment can be repeated in a month.
The general length of the treatment is indicated by a medical state of the patients and sensitivity of the microorganisms to the action of Rifaximin.
If glutamyl pyruvic transaminase (liver enzyme) is increased in the blood during the use of Xifaxan, it can specify a negative effect of Rifaxamin to liver. It is needed to inform a doctor about that and have a medical examination. If it is confirmed, the treatment should be stopped.